QIAGEN N.V.
QGENQIAGEN N.V. is a global provider of sample and assay technologies, serving the life sciences and molecular diagnostics markets. The company specializes in sample preparation, gene detection, and bioinformatics solutions designed for research, clinical, and molecular testing applications. QIAGEN's products facilitate the analysis of biological samples to detect, diagnose, and monitor diseases, making it a key player in advancing personalized healthcare and molecular diagnostics.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| $1.26 | 2025-01-29 | ||
| $1.04 | 2017-01-25 | ||
| $2.29 | 2026-01-08 | ||
| July 14, 2026 | $0.35 | 2026-07-07 | 2026-07-07 |
| July 10, 2025 | $0.25 | 2025-07-02 | 2025-07-02 |
Dividends Summary
- Total Returned Value: Investors who held QGEN shares during this period received a total of $5.19 per share in dividend income.
- Latest Payout: The most recent dividend of $1.26/share was paid 4 days ago, on July 14, 2026.
- Dividend Growth: Since 2025, the dividend payout has grown by 404.0%, from $0.25 to $1.26.
Company News
The global cancer biomarkers market is valued at USD 28.25 billion in 2026 and is projected to reach USD 54.48 billion by 2032, expanding at an 11.6% CAGR. Growth is driven by rising cancer incidence, technological advances, adoption of precision medicine, and liquid biopsy techniques. Omics technologies and breast cancer diagnostics lead segment...
The global environmental DNA (eDNA) market is expected to grow at a CAGR of 10.2% from 2026 to 2031, driven by non-invasive species detection methods, stricter environmental regulations, and increasing demand for ecosystem health monitoring. North America leads the market with advanced research infrastructure and strong public-private collaborati...
The global molecular biology enzymes, reagents and kits market is projected to grow from USD 27.69 billion in 2025 to USD 70.85 billion by 2035, with a CAGR of 9.68%. Growth is driven by increasing adoption of precision medicine, molecular diagnostics, genomics research, and biotechnology R&D. The US market is expected to reach $23.54 billion and...
The global bloodstream infection testing market is expected to grow at a CAGR of 4.80% through 2035, driven by rising sepsis cases, antimicrobial stewardship mandates, and adoption of rapid molecular diagnostics. North America leads the market, with the U.S. contributing 87.4% of regional revenues, while Asia Pacific shows the fastest growth. Key...
The global Enteric Disease Testing Market is valued at USD 4.08 billion in 2025 and is projected to reach USD 5.86 billion by 2035, growing at a CAGR of 3.70%. Growth is driven by increasing foodborne and waterborne disease prevalence, rising demand for rapid pathogen detection, and expanding adoption of multiplex molecular diagnostics. North Ame...
